CoreCap Advisors LLC Grows Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

CoreCap Advisors LLC grew its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 8,870.0% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 35,880 shares of the biopharmaceutical company’s stock after buying an additional 35,480 shares during the period. CoreCap Advisors LLC’s holdings in Catalyst Pharmaceuticals were worth $749,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the stock. Steward Partners Investment Advisory LLC purchased a new stake in Catalyst Pharmaceuticals in the 4th quarter worth approximately $27,000. Farther Finance Advisors LLC increased its stake in shares of Catalyst Pharmaceuticals by 125.1% in the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock worth $56,000 after purchasing an additional 1,495 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter valued at $65,000. KBC Group NV lifted its stake in Catalyst Pharmaceuticals by 48.8% in the 4th quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 1,542 shares in the last quarter. Finally, Quarry LP purchased a new position in shares of Catalyst Pharmaceuticals during the fourth quarter valued at about $104,000. Institutional investors own 79.22% of the company’s stock.

Insider Buying and Selling

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 44,904 shares of the company’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the completion of the sale, the insider now directly owns 68,873 shares in the company, valued at approximately $1,521,404.57. This represents a 39.47 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Brian Elsbernd sold 62,975 shares of the firm’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.50. Following the transaction, the insider now owns 188,564 shares in the company, valued at approximately $4,333,200.72. This represents a 25.04 % decrease in their position. The disclosure for this sale can be found here. 10.40% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. HC Wainwright reissued a “buy” rating and set a $35.00 price target on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Robert W. Baird lifted their price target on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an “outperform” rating in a research note on Monday, March 3rd. Baird R W raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Monday, February 3rd. Stephens reissued an “overweight” rating and issued a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Finally, StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, February 28th. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $32.29.

Catalyst Pharmaceuticals Stock Performance

Shares of NASDAQ:CPRX opened at $23.37 on Friday. The firm’s 50 day simple moving average is $22.99 and its 200-day simple moving average is $22.39. Catalyst Pharmaceuticals, Inc. has a one year low of $14.75 and a one year high of $26.16. The firm has a market cap of $2.85 billion, a PE ratio of 19.81, a price-to-earnings-growth ratio of 3.31 and a beta of 0.70.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.